San Francisco, CA, United States of America

Martin Vanderlaan

USPTO Granted Patents = 13 

 


Average Co-Inventor Count = 3.8

ph-index = 8

Forward Citations = 157(Granted Patents)


Company Filing History:


Years Active: 2009-2025

Loading Chart...
Loading Chart...
Loading Chart...
13 patents (USPTO):Explore Patents

Title: Martin Vanderlaan: Innovator in Recombinant Polypeptides

Introduction

Martin Vanderlaan, an esteemed inventor based in San Francisco, CA, has made significant contributions to the field of biopharmaceuticals. With an impressive portfolio of 13 patents, his work primarily focuses on recombinant polypeptides, particularly in the development of therapeutic antibodies.

Latest Patents

Among Martin’s latest patents are groundbreaking innovations involving methods and compositions comprising purified recombinant polypeptides. These patents include:

1. **Methods and Compositions Comprising Purified Recombinant Polypeptides** - This patent focuses on purified recombinant polypeptides isolated from Chinese hamster ovary host cells, including antibodies such as therapeutic antibodies, and outlines methods for making and employing these polypeptides.

2. **Methods of Purifying Recombinant Anti-Abeta Antibodies** - This patent also emphasizes purified recombinant polypeptides derived from the same source and highlights methods for purification and application of these antibodies.

Career Highlights

Martin Vanderlaan is currently affiliated with Genentech, Inc., a leading biotechnology company renowned for its innovative therapies and advancements in health care. His work has been instrumental in enhancing the efficacy and safety of therapeutic proteins, thereby impacting patient care positively.

Collaborations

Throughout his career, Martin has collaborated with notable experts in his field, including Christopher Yu and Susan C. Fisher. These collaborations reflect a team-oriented approach to innovation, fostering an environment where complex biopharmaceutical challenges can be tackled effectively.

Conclusion

In conclusion, Martin Vanderlaan stands out as a key figure in the realm of recombinant polypeptides and therapeutic antibodies. His 13 patents not only underscore his ingenuity but also contribute to the ongoing evolution of medical treatments. His role at Genentech, Inc. and collaborations with esteemed colleagues further amplify his influence in the biopharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…